Stock Events

Stock Events

Global X S&P Biotech 

A$73.74
13
-A$1.62-2.15% 04:28 Today

Statistics

Day High
75.2
Day Low
73.5
52W High
81.49
52W Low
56.29
Volume
2,739
Avg. Volume
2,109
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Expense Ratio

0.45%
0%
1%+
The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Dividends

0%Dividend Yield
Jul 2022
A$0.02
Jul 2021
A$6.26
Jul 2020
A$6.76
Jul 2019
A$1.17
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CURE.AU. It's not an investment recommendation.
BetaShares NASDAQ 100
4
NDQ.AU
BlackRock Australia iShares S&P 500
4
IVV.AU
Global X FANG+
4
FANG.AU
BetaShares S&P/ASX 200 Resources Sector
4
QRE.AU

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
iShares Biotechnology
IBB
Mkt Cap0
Tracks the performance of a biotech index, directly competing with CURE.AU's focus on biotech sector investments.
State Street SPDR S&P Biotech
XBI
Mkt Cap0
SPDR Series Trust ETF that targets the biotechnology industry, offering a similar investment profile to CURE.AU.
VanEck Biotech
BBH
Mkt Cap0
VanEck Vectors ETF focusing on biotech, competes by investing in large biotech firms similar to those in CURE.AU's portfolio.
First Trust NYSE Arca Biotechnology Index Fund
FBT
Mkt Cap0
First Trust Amex Biotechnology Index Fund, competes by tracking a biotech index, offering an alternative to CURE.AU's strategy.
Principal Healthcare Innovators Index
BTEC
Mkt Cap0
Principal Healthcare Innovators Index ETF, focuses on emerging biotech companies, providing a competitive investment alternative.
Direxion Daily S&P Biotech Bull 3X
LABU
Mkt Cap0
Direxion Daily S&P Biotech Bull 3X Shares, offers leveraged exposure to biotech, competing for investors seeking higher risk/reward.
Direxion Daily S&P Biotech Bear 3X
LABD
Mkt Cap0
Direxion Daily S&P Biotech Bear 3X Shares, inverse/leveraged competitor, appealing to investors with a bearish outlook on biotech.
Invesco Biotechnology & Genome
PBE
Mkt Cap0
Invesco Dynamic Biotechnology & Genome ETF, competes by investing in biotech and genome companies, similar to CURE.AU's focus.
ALPS Medical Breakthroughs
SBIO
Mkt Cap0
ALPS Medical Breakthroughs ETF, focuses on small and mid-cap biotech companies, offering a niche alternative to CURE.AU.
Virtus Biotech
BBP
Mkt Cap0
Virtus LifeSci Biotech Products ETF, competes by investing in companies with principal business in biotech product development.

Holdings

Regions

Sectors

About

The Global X S&P Biotech ETF, identified by its ticker CURE, endeavors to replicate the overall financial performance, encompassing both capital gains and dividends, of the S&P Biotechnology Select Industry Index, before any management fees and operational costs are deducted.
Show More
CEO
Country
Australia
ISIN
AU0000028110

Listings

AU
AU
CURE.AU

0 Comments

Share your thoughts

FAQs

What is Global X S&P Biotech stock price today?▼
The current price of CURE.AU is A$73.74 AUD — it has decreased by -2.15% in the past 24 hours. Watch Global X S&P Biotech stock price performance more closely on the chart.
What is Global X S&P Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Australia Exchange exchange Global X S&P Biotech stocks are traded under the ticker CURE.AU.
Is Global X S&P Biotech stock price growing?▼
CURE.AU stock has risen by +1.23% compared to the previous week, the month change is a -2.48% fall, over the last year Global X S&P Biotech has showed a +26.33% increase.
Does Global X S&P Biotech pay dividends?▼
Yes, CURE.AU dividends are paid annual. The last dividend per share was 0.02 . As of today, Dividend Yield (FWD)% is 0%.
In which sector is Global X S&P Biotech located?▼
Global X S&P Biotech operates in the Finance & Payments sector.
When did Global X S&P Biotech complete a stock split?▼
Global X S&P Biotech has not had any recent stock splits.
Where is Global X S&P Biotech headquartered?▼
Global X S&P Biotech is headquartered in Sydney, Australia.